期刊文献+

乳腺癌患者血浆微泡BCRP mRNA水平对化疗疗效的预测价值分析

Predictive value analysis of BCRP mRNA levels in plasma microbubble on the efficacy of chemotherapy of breast cancer patients
暂未订购
导出
摘要 目的分析乳腺癌患者血浆微泡乳腺癌耐药蛋白(BCRP)mRNA水平对化疗疗效的预测价值。方法50例乳腺癌化疗患者作为观察组,另选取同时间段进行体检的50例健康人作为对照组。对比两组研究对象的血浆微泡BCRP mRNA相对含量;对比观察组癌组织及癌旁健康组织的增殖基因Bcl-2、Survivin与凋亡基因Caspase-3、Caspase-9的mRNA含量;分析观察组血浆微泡BCRP含量与增殖基因Bcl-2、Survivin及凋亡基因Caspase-3、Caspase-9 mRNA的相关性。结果观察组的血浆微泡BCRP mRNA相对含量为(255.42±35.17),显著高于对照组的(100.00±15.58),差异具有统计学意义(P<0.05)。癌组织的增殖基因Bcl-2、Survivin的mRNA含量分别为(310.23±43.24)、(241.13±35.05),均显著高于癌旁健康组织的(100.00±13.31)、(100.00±15.11),凋亡基因Caspase-3、Caspase-9的mRNA含量分别为(35.07±4.05)、(25.54±3.02),均显著低于癌旁健康组织的(100.00±14.12)、(100.00±15.20),差异均具有统计学意义(P<0.05)。血浆微泡中的BCRP mRNA含量与增殖基因Bcl-2、Survivin的mRNA含量呈正相关(r=0.748、0.714,P<0.05),与凋亡基因Caspase-3、Caspase-9的mRNA含量呈负相关(r=-0.785、-0.693,P<0.05)。结论血浆微泡BCRP mRNA水平和乳腺癌化疗耐药性及发生存在相关性,BCRP mRNA含量水平越高则化疗效果越差,BCRP mRNA含量水平可作为预测化疗疗效的指标。 Objective To analyze the predictive value analysis of breast cancer resistant protein(BCRP)mRNA levels in plasma microbubble on the efficacy of chemotherapy of breast cancer patients.Methods There were 50 patients with breast cancer treated with chemotherapy selected as the observation group,and another 50 healthy people who had physical examination in the same period selected as the control group.The relative content of BCRP mRNA in plasma microbubble was compared between the two groups,and the mRNA content of the proliferative genes Bcl-2,Survivin,and apoptotic genes Caspase-3,Caspase-9 in the cancer tissues and healthy tissues adjacent to the cancer of the observation group was compared.Correlation between BCRP content in plasma microbubble and proliferation genes Bcl-2,Survivin,apoptosis genes Caspase-3,Caspase-9 mRNA in the observation group were analyzed.Results The relative content of BCRP mRNA in plasma microbubble was(255.42±35.17)in the observation group,which was significantly higher than(100.00±15.58)in the control group,and the difference was statistically significant(P<0.05).The mRNA content of the proliferative genes Bcl-2 and Survivin in cancer tissues were(310.23±43.24)and(241.13±35.05),which were significantly higher than those in healthy tissues adjacent to the cancer(100.00±13.31)and(100.00±15.11).The mRNA contents of the genes Caspase-3 and Caspase-9 were(35.07±4.05)and(25.54±3.02),which were significantly lower than(100.00±14.12)and(100.00±15.20)of healthy tissues adjacent to the cancer.Their differences was statistically significant(P<0.05).The content of BCRP mRNA in plasma microvesicles was positively correlated with the mRNA levels of proliferating genes Bcl-2 and Survivin(r=0.748,0.714,P<0.05),and negatively correlated with the mRNA levels of apoptosis genes Caspase-3 and Caspase-9(r=-0.785,-0.693,P<0.05).Conclusion There is a correlation between BCRP mRNA levels in plasma microbubble and the resistance and occurrence of chemotherapy in breast cancer.The higher the BCRP mRNA level,the worse the chemotherapy effect.The BCRP mRNA level can be used as an index to predict the efficacy of chemotherapy.
作者 苏瑞真 徐月红 SU Rui-zhen;XU Yue-hong(Department of Pharmacy,Fifth Affiliated Hospital of Guangzhou Medical University,Guangzhou 510000,China)
出处 《中国实用医药》 2020年第3期18-20,共3页 China Practical Medicine
关键词 乳腺癌 乳腺癌耐药蛋白 化疗疗效 预测价值 Breast cancer Breast cancer resistant protein Efficacy of chemotherapy Predictive value
  • 相关文献

参考文献14

二级参考文献104

  • 1张彦收,刘运江.乳腺癌组织中BCRP的表达与新辅助化疗疗效的关系[J].肿瘤防治研究,2014,41(5):434-438. 被引量:7
  • 2Doyle L, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP ( ABCG2 ) [ J ]. Oncogene, 2003,22 ( 47 ) : 7340-7358.
  • 3Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid turnouts: revised RECIST guideline ( version 1.1 ) [ J]. Eur J Cancer,2009,45 (2) :228-247.
  • 4Aharon A, Brenner B. Microparticles, thrombosis and cancer[ J ]. Best Pract Res ClinHaemato1,2009,22 ( 1 ) :61-69.
  • 5Alfaras I, Perez M, Juan ME, et al. Involvement of Breast Cancer Resistance Protein (BCRP1/ABCG2) in the Bio- availability and Tissue Distribution of frans-Resveratrol in Knockout Mice[J]. J Agric Food Chem, 2010, 58(7): 4523- 4528.
  • 6Eisenhauer EA, Therasse P, Boqaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guide- line (version 1,1)[J]. Eur J Cancer, 2009, 45(2): 228-247.
  • 7Soliman AA, Csorba R, Ullrich A, et al. Antiphopholipid an- tibodies and functional activated protein C resistance in pa- tients with breast cancer during anthracycline-based chemo- therapy administered through an intravenous port-catheter device[J]. Clin Appl Thromb Hemost, 2014, 20(3): 338-340.
  • 8Ginguene C, Champier J, Maallem S, et al. P-glycoprotein (ABCB 1) and breast cancer resistance protein (ABCG2) lo- calize in the microvessels forming the blood-tumor barrier in ependymomas[J]. Brain Pathol, 2010, 20(5): 926-935.
  • 9Mears R, Craven RA, Hanrahan S, et al. Proteomic analy- sis of melanoma-derived exosomes by two-dimensionalpolyacrylamide gel electrophoresis and mass spectrometry [J]. Proteomics, 2004, 4(12): 4019-4031.
  • 10A1-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRvlII by microvesi- cles derived from tumour cells[J]. Nat Cell Biol, 2008, 10 (5): 619-624.

共引文献108

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部